Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 15/20 | 1.00 |
| ▸ | KDR | P35968 | 6/20 | 0.77 |
| ▸ | RET | P07949 | 4/20 | 0.77 |
| ▸ | SRC | P12931 | 3/20 | 0.77 |
| ▸ | MAPT | P10636 | 4/20 | 0.75 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.75 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.75 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.75 |
| ▸ | FBP1 | P09467 | 3/20 | 0.75 |
| ▸ | EPHB2 | P29323 | 2/20 | 0.75 |
| ▸ | ABL1 | P00519 | 2/20 | 0.75 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.75 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.75 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.75 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.75 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.75 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.75 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.75 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31060707 | 1.00 | EGFR (1.00) | EGFRKDRRETSRCMAPT | |
| Hydrochloric Acid SCHEMBL5478587 | 0.99 | EGFR (0.97) | EGFRKDRRETSRCMAPT | |
| SCHEMBL8871277 | 0.92 | EGFR (0.84) | EGFRKDRRETSRCMAPT | |
| SCHEMBL2099775 | 0.91 | EGFR (0.83) | EGFRKDRRETSRCMAPT | |
| SCHEMBL2100551 | 0.90 | EGFR (0.82) | EGFRKDRRETSRCMAPT | |
| SCHEMBL1418218 | 0.90 | EGFR (0.82) | EGFRKDRRETSRCMAPT | |
| SCHEMBL2102382 | 0.90 | EGFR (0.82) | EGFRKDRRETSRCMAPT | |
| SCHEMBL8870651 | 0.90 | EGFR (0.81) | EGFRKDRRETSRCMAPT | |
| SCHEMBL2101009 | 0.90 | EGFR (0.81) | EGFRKDRRETSRCMAPT | |
| SCHEMBL8870965 | 0.90 | EGFR (0.81) | EGFRKDRRETSRCMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513267-B2 | 4-anilinoquinazoline derivatives with adenosine-kinase inhibitor properties | UNIVERSIDADE ESTADUAL DE CAMPINAS-UNICAMP (BR) | 2013-08-20 | — | — | US | disclosed |
| US-8309133-B2 | Nanoparticulate quinazoline derivative formulations | ALKERMES PHARMA IRELAND LIMITED (IE) | 2012-11-13 | — | — | US | disclosed |
| US-8309133-B2 | Nanoparticulate quinazoline derivative formulations | ALKERMES PHARMA IRELAND LIMITED (IE) | 2012-11-13 | — | — | US | disclosed |
| EP-1737832-B1 | 4-ANILINOQUINAZOLINE DERIVATIVES WITH ADENOSINE-KINASE INHIBITORY PROPERTIES | UNICAMP (BR) | 2011-12-14 | — | — | EP | disclosed |
| US-20100292209-A1 | METHODS FOR IDENTIFYING COMPOUNDS THAT MODULATE NEUROTROPHIC FACTOR SIGNALING | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2010-11-18 | — | — | US | disclosed |
| US-20070060600-A1 | 4-Anilinequinazolines with adenosine-kiase inhibitor properties | UNIVERSIDADE ESTADUAL DE CAMPINAS-UNICAMP (BR) | 2007-03-15 | — | — | US | disclosed |
| EP-0907885-B1 | METHOD OF COMPARATIVE SCREENING OF PHARMACOLOGICALLY ACTIVE SUBSTANCES | BOEHRINGER INGELHEIM INT (DE) | 2003-09-03 | — | — | EP | disclosed |
| EP-0816848-A1 | Method for comparative screening of substances with pharmacological activity | BOEHRINGER INGELHEIM INTERNATIONAL GmbH (DE) | 1998-01-07 | — | — | EP | disclosed |
| US-5616582-A | Use as anticancer agents; e.g. gefitinib | ZENECA LIMITED (GB) | 1997-04-01 | — | — | US | disclosed |
| EP-0566226-B1 | Quinazoline derivatives | ZENECA LTD (GB) | 1995-11-08 | — | — | EP | disclosed |
| US-5457105-A | anticancer use; e.g. 4-(3'-chloro-4'-fluoroanilino)-6,7-dimethoxyquinazoline (gefitinib) | ZENECA LIMITED (GB) | 1995-10-10 | — | — | US | disclosed |
| EP-0566226-A1 | Quinazoline derivatives | ZENECA LIMITED (GB) | 1993-10-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060600-A1 | 4-Anilinequinazolines with adenosine-kiase inhibitor properties | ADK, AK1, ADORA3 | EGFR 3142/4885KDR 1289/4885RET 3198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.